Sign Up Now to Download a Free Research Report on BPAX
Sign-Up for a Free Report
Having problems viewing PDF files? BioSante Pharmaceuticals, Inc.
BioSante is developing a portfolio of cancer vaccines, with 17 Phase I and Phase II clinical trials currently on-going. Four of these vaccines have been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA). In March the company reported that its net loss was $51.6 million or $0.52 per share for the year ended December 31, 2011, compared to a net loss of $46.2 million or $0.70 per share for 2010.
Going forward ... (see research report)
Subscribe to News Feeds